New radioactive bullet targets Hard-to-Treat prostate cancer

NCT ID NCT04644770

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals are to find a safe dose and check for side effects, with some early signs of effectiveness also being measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-69086420 (a drug that delivers a radioactive particle to prostate cancer cells)
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong: This is a very early phase 1 trial, so the main goal is safety, not effectiveness. The drug may cause serious side effects or not shrink tumors. It is also only for a specific type of advanced prostate cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma metastatic prostate carcinoma prostate adenocarcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA PROSTATIC NEOPLASMS

Contacts and locations

Locations

Case Western Reserve University

Cleveland, Ohio, 44106, United States
City of Hope

Duarte, California, 91010, United States
East Jefferson General Hospital

Metairie, Louisiana, 70006, United States
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Tulane University Hospital & Clinics

New Orleans, Louisiana, 70112, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Utah Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
XCancer Omaha / Urology Cancer Center

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.